For laboratory and research use only. Not for human consumption.
Skin & Hair

Oligopeptide-1

Also known as: sh-Oligopeptide-1, rh-Oligopeptide-1, EGF, Epidermal Growth Factor, rhEGF, Recombinant human EGF

Clinical Trials
Share:
Last reviewed

Key Facts: Oligopeptide-1

Category
Skin & Hair
FDA Status
Not FDA Approved
Clinical Status
Cosmetic use - Widely available in skincare (EGF serums). Cosmetic ingredient, not an FDA-approved drug. Medical rhEGF products have been studied for wounds, but cosmetic EGF for skin aging is not an approved drug use, and controlled trials are few.
Banned in Sport (WADA)
Not named on the WADA Prohibited List (2026). Topical cosmetic EGF is not a known anti-doping issue, but WADA prohibits growth factors that affect muscle, tendon or ligament protein synthesis, vascularisation or regenerative capacity under S2.3 (Growth factors and growth factor modulators), so injecting EGF would be a real risk for tested athletes.
Administration
Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic
Typical Dose
Low parts-per-million concentration in a serum
Frequency
Once or twice daily
Duration
Studies typically ran 4 to 12 weeks
Also Known As
sh-Oligopeptide-1, rh-Oligopeptide-1, EGF, Epidermal Growth Factor, rhEGF, Recombinant human EGF

How does Oligopeptide-1 work?

EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there.

What does the research show?

A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

What doses have been studied?

Human Trials·Many small human studies, but mostly uncontrolled or non-randomized; few vehicle-controlled trials

Typical Dosingⓘ

Community experience

Common Dose

Low parts-per-million concentration in a serum

Range

Not standardized

Frequency

Once or twice daily

Because EGF degrades easily, storage matters (cool, sealed, used before expiry). Many studies applied it right after microneedling or laser, which is not the same as rubbing it on intact skin.

Research Dosingⓘ

Scientific studies

Cosmetic formulation levels, not a dose recommendation

Doses from Studies

Duration

Studies typically ran 4 to 12 weeks

Administration

Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic

When and how is Oligopeptide-1 taken?

Best Time to Take

Evening skincare routine, or right after an in-clinic procedure

Once or twice daily on clean skin

Food Recommendation

With or without food

Why This Timing?

No data showing time of day matters. Many studies used it after procedures when the skin barrier is open, which is also when irritation is most likely.

What are the side effects of Oligopeptide-1?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Mild redness, burning or itching (transient)
  • ●Irritation, especially when used after microneedling
  • ●Theoretical concern about stimulating existing abnormal or cancerous skin cells (unproven, but untested long term)
  • ●People with skin cancer history, many atypical moles, or psoriasis should ask a dermatologist first

References

Research This Peptide Further

Frequently Asked Questions

What does Oligopeptide-1 do?

sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.

How does Oligopeptide-1 work?

EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there.

Is Oligopeptide-1 FDA approved?

No, Oligopeptide-1 is not currently FDA approved. Current status: Cosmetic use - Widely available in skincare (EGF serums). Cosmetic ingredient, not an FDA-approved drug. Medical rhEGF products have been studied for wounds, but cosmetic EGF for skin aging is not an approved drug use, and controlled trials are few.

Is Oligopeptide-1 banned in sport?

Not named on the WADA Prohibited List (2026). Topical cosmetic EGF is not a known anti-doping issue, but WADA prohibits growth factors that affect muscle, tendon or ligament protein synthesis, vascularisation or regenerative capacity under S2.3 (Growth factors and growth factor modulators), so injecting EGF would be a real risk for tested athletes.

What are the side effects of Oligopeptide-1?

Reported side effects include: Mild redness, burning or itching (transient), Irritation, especially when used after microneedling, Theoretical concern about stimulating existing abnormal or cancerous skin cells (unproven, but untested long term), People with skin cancer history, many atypical moles, or psoriasis should ask a dermatologist first. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Oligopeptide-1?

Community-reported common dose: Low parts-per-million concentration in a serum (Once or twice daily). Range: Not standardized. Administration: Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Oligopeptide-1 or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Palmitoyl Tripeptide-38

Research

Palmitoyl tripeptide-38 is the active in Sederma's Matrixyl synthe'6, a newer member of the Matrixyl family launched around 2011. It is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. It is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it.

Skin & Hair

Acetyl Tetrapeptide-5

Research

Acetyl tetrapeptide-5 is a short synthetic peptide sold by Lipotec (now Lubrizol) as Eyeseryl, made for eye creams that target under-eye puffiness. The pitch is that it reduces fluid leaking into the tissue under the eyes. It is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it.

Skin & Hair

Want updates on Oligopeptide-1 research?

Get an email when we add new research here, when it is back in stock, or when the price drops.